Clinical Trials Logo

Nephrosis clinical trials

View clinical trials related to Nephrosis.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06443034 Not yet recruiting - Nephrotic Syndrome Clinical Trials

Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1

NEPHROL1
Start date: June 30, 2024
Phase:
Study type: Observational

This is a multicentric retrospective observational cohort study. As primary objective, the study aims to evaluate the factors associated with nephrotic syndrome remission in patient with nephrotic syndrome, biopsy-prove minimal change disease or focal segmental glomerulosclerosis, and an at-risk variant of the APOL1 gene. As secondary objectives, this study aims: - To evaluate the benefit of corticosteroids in obtaining the remission of nephrotic syndrome - To identify the predictors of complete renal remission of nephrotic syndrome - To evaluate the benefit of corticosteroids in reducing the incidence of end-stage renal disease - To assess the adverse events of corticosteroids in patients treated with corticosteroids.

NCT ID: NCT06334692 Not yet recruiting - Nephrotic Syndrome Clinical Trials

Autoantibodies Against-nephrin in Idiopathic Nephrotic Syndrome

BLINDER
Start date: May 2024
Phase:
Study type: Observational

This retrospective study is aimed at evaluating the levels of circulating anti-nephrin autoantibodies in patients with INS, including those with MCD/FSGS and in patients who have experienced relapse of FSGS post-transplant, compared to those of a control group of patients with nephrotic syndrome due to primary membranous nephropathy (MN).

NCT ID: NCT06315504 Not yet recruiting - Nephrotic Syndrome Clinical Trials

Circulating Factors in Nephrotic Syndrome

Start date: April 1, 2024
Phase:
Study type: Observational [Patient Registry]

A prospective observational study to investigate the treatment-associated changes of circulating factors associated with glomerular diseases among patients with de novo nephrotic syndrome admitted to hospital for a kidney biopsy.

NCT ID: NCT06256471 Not yet recruiting - Parasitic Disease Clinical Trials

The Impact of Parasitic Infection on Multiple Sclerosis and Nephrotic Syndrome

Start date: June 1, 2024
Phase:
Study type: Observational

1. Detection of the prevalence of parasitic infections amoung patients with multiple sclerosis and nephrotic syndrome at Assiut University Hospitals. 2. Detection of the effect of parasitic infections on these diseases courses. 3. Inform authorities about the importance of management of parasitic infections in those patients.

NCT ID: NCT06185257 Not yet recruiting - Clinical trials for Chronic Renal Disease and Nephrotic Syndrome

Electroencephalographic Changes in Nonconvulsive Children With Chronic Renal Disease

Start date: February 15, 2024
Phase:
Study type: Observational

Chronic kidney disease (CKD) arises from many heterogeneous disease pathways that alter the function and structure of the kidney irreversibly, over months or years. The diagnosis of CKD rests on establishing a chronic reduction in kidney function and structural kidney damage. The best available indicator of overall kidney function is glomerular filtration rate (GFR), which equals the total amount of fluid filtered through all of the functioning nephrons per unit of time The definition and classification of CKD have evolved over time, but current international guidelines define CKD as decreased kidney function shown by GFR of less than 60 mL/min per 1·73 m2, or markers of kidney damage, or both, of at least 3 months duration, regardless of underlying cause . When GFR is less than 15 mL/min per 1·73m2 , a person has reached end stage kidney disease (ESKD), at which point kidney function is no longer able to sustain life over the long term. Options for patients with ESKD are kidney replacement therapy (in the form of dialysis or kidney transplantation), or conservative care (also called palliation or non-dialytic care Encephalopathy detected in patients with chronic kidney disease results from their exposure to several factors, such as uremia, hypertension, and fluid, and electrolyte disturbances (Brouns R, DyDeyn pp,2004) Uremic encephalopathy features include alterations of mental status (alertness and awareness alterations, poor concentration, psychosis, and hallucinations, without treatment of which stupor, and coma may develop) and motor system abnormalities, such as clouding of the sensorium as an early feature and delirium, seizures, and coma as late features (Palmer sc ,etal,2010)EEG is useful in assessing patients in uremic encephalopathy and in monitoring their progress. Electroencephalographic (EEG) findings correlate with clinical symptoms and, therefore, may be of diagnostic value. In addition, it can be useful to exclude other causes of confusion such as infection or structural abnormalities (Dijck Annemie Van,etal,2012). The EEG in uremic encephalopathy is generally abnormal, showing generalized slowing that becomes more severe as the condition worsens. EEG in CKD usually shows irregular low voltage with slowing of the posterior dominant alpha rhythm and occasional theta bursts. Prolonged bursts of bilateral, synchronous slow and sharp waves or spike and waves are characteristic. These changes stabilize with dialysis. EEG abnormalities in uremic encephalopathy is reflected through appearance of theta waves, disappearance of normal basic rhythms and diminished reactivity of EEG to afferent stimulation and domination by generalized delta activity. All these changes are mostly appreciated in the frontal leads (Al Arieff,Philadelphia,Ssaunders,2004)(Cl fraser, Arieff,Philadelphia,2001) A lot of studies have been done about uremic encephalopathy in acute renal failure patients. Very few data are available regarding EEG changes in CKD. This study evaluates the EEG findings in different stages of CKD.

NCT ID: NCT06130631 Not yet recruiting - Clinical trials for Nephrotic Syndrome in Children

Predictors of Steroid Response in Childhood Nephrotic Syndrome

Start date: December 3, 2023
Phase:
Study type: Observational

Retrospective study of predictors of steroid response in childhood nephrotic syndrom

NCT ID: NCT05966818 Not yet recruiting - Nephrotic Syndrome Clinical Trials

Effect of Dapagliflozin in Non-Diabetic Patients With Nephrotic Syndrome.

Start date: August 1, 2023
Phase: Phase 4
Study type: Interventional

Dapagliflozin is the first SGLT2 inhibitor to be approved for CKD treatment regardless of diabetes status. Since many etiologies of non-diabetic nephropathy are characterized by intraglomerular hypertension, it was hypothesized that dapagliflozin acutely decreases GFR and proteinuria in patients without diabetes at risk of progressive kidney function loss such as nephrotic patients via a glucose independent hemodynamic mechanism. The aim of the study is to assess the effect of Dapagliflozin on proteinuria and estimated glomerular filtration rate in non-diabetic patients with nephrotic syndrome in order to slow the decline in kidney function and the progression to ESRD and to prevent the complications of nephrotic syndrome like thrombotic diseases, peritonitis, hyperuricemia, and recurrent infections.

NCT ID: NCT05904197 Not yet recruiting - Nephrotic Syndrome Clinical Trials

Effectiveness of Educational Gamified Cards About Nephrotic Syndrome

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

This study aims to evaluate the effectiveness of educational innovative gamified cards about nephrotic syndrome for school age children on their outcomes and caregivers' practices

NCT ID: NCT05850546 Not yet recruiting - Clinical trials for Steroid-Sensitive Nephrotic Syndrome

Rituximab in the First Episode of Paediatric Nephrotic Syndrome

Start date: April 1, 2024
Phase: Phase 3
Study type: Interventional

The study will be a randomized, open-label trial in children with the initial episode of SSNS and whose state of complete remission after received standard prednisolone, to determine whether rituximab (a single intravenous infusion of 375 mg/m2) would be noninferior to corticosteroid alone in maintaining complete disease remission during 12-month of follow-up.

NCT ID: NCT05797051 Not yet recruiting - Clinical trials for Diabetic Nephropathies

Application of Hyperspectral Imaging in the Diagnosis of Glomerular Diseases

Start date: May 30, 2023
Phase:
Study type: Observational

Morning urine samples of patients with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy, and minimal degenerative nephropathy confirmed by renal needle biopsy in our hospital from November 2020 to January 2022 were collected. By scanning the morning urine samples of corresponding patients with microhyperspectral imager, machine learning and deep learning were used to classify microhyperspectral images, and the classification accuracy was greater than 85%. Thus, hyperspectral imaging technology could be used as a non-invasive diagnostic means to assist the diagnosis of glomerular diseases.